1:00 – 1:10 PM

Welcome & Market Overview

Presented By:
Thomas Ciulla, MD, MBA, Clinical Professor of Ophthalmology, Volunteer - Indiana University School of Medicine / Vitreoretinal Medicine and Surgery - Midwest Eye Institute

1:10 – 2:15 PM

Company Showcase

Adverum Biotechnologies | Aaron Osborne, MBBS - Chief Medical Officer
Ocugen | Shankar Musunuri, PhD, MBA - Chairman, CEO & Co-Founder
SparingVision | Stéphane Boissel - CEO
Eyevensys | Francine Behar-Cohen, MD, PhD - Founder & Chief Innovation Officer
AGTC | Sue Washer - President & CEO
GenSight Biologics | Magali Taiel, MD - Chief Medical Officer
Iveric Bio | Pravin Dugel, MD - EVP & Chief Strategy and Business Officer
REGENXBIO | Steve Pakola, MD - Chief Medical Officer

2:15 – 3:05 PM

Gene Therapy Outlook Panel

Peter Francis MD, PhD, Chief Scientific Officer & Therapeutic Area Head, Ophthalmology/Retina - 4D Molecular Therapeutics
Jeffrey S. Heier, MD, Director, Retina Service & Retina Research - Ophthalmic Consultants of Boston
Arshad Khanani, MD, Director of Clinical Research - Sierra Eye Associates / Clinical Associate Professor - University of Nevada
Jose-Alain Sahel, MD, The Eye and Ear Endowed Chair Distinguished Professor and Chairman & Director, Department of Ophthalmology, UPMC Eye Center - University of Pittsburgh School of Medicine
Glenn Yiu, MD, PhD, Associate Professor, Department of Ophthalmology - UC Davis Health

Moderated By:
Thomas Ciulla, MD, MBA, Clinical Professor of Ophthalmology, Volunteer - Indiana University School of Medicine / Vitreoretinal Medicine and Surgery - Midwest Eye Institute

3:05 – 4:00 PM

Virtual Networking


Silver Sponsor

Promedica International

Promedica International is a privately held, full-service, ISO-certified CRO providing clinical trial services for the medical device, biotechnology and pharmaceutical industries. Founded in 1985, Promedica International, a woman-owned corporation, is headquartered in Orange County, California. We have successfully been providing exceptional value to our clients for over 30 years in clinical trial project management, site recruitment and management, clinical study monitoring, data management, biostatistics, medical writing and GCP auditing.

Bronze Sponsors


Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients.

GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.


REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform to address genetic diseases through two modalities: AAV-mediated antibody delivery and monogenic gene replacement. We believe this platform forms a strong foundation for our current programs and with our ongoing research and development, we expect to continue to expand the platform.